Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Carboplatin in combination with Paclitaxel, Pertuzumab, and Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description
Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2). NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab, paclitaxel, and carboplatin (TRAIN-2) for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive, locally advanced, inflammastory, or early stage breast cancer at high risk of recurrence in adult patients.
Pertuzumab and Trastuzumab (Phesgo), PACLitaxel and CARBOplatin Therapy (TRAIN-2). NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab and trastuzumab (phesgo) in combination with paclitaxel and carboplatin for reimbursement as a treatment option for the treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.